Sydney-based Recce Pharmaceuticals Ltd (ASX:RCE) has found that its synthetic anti-infective drug RECCE® 327 (or R327) is effective in treating bacterial growth – specifically Escherichia coli (E.coli) – following a Phase I/II clinical trial on urinary tract infections and urosepsis.
During the Phase I/II rapid infusion trial, 25 patients were dosed with up to 4,000mg of R327, with the highest dose cohort comprising six people, and doses being administered intravenously across various infusion times – 15-minutes, 20-minutes, 30-minutes and 45-minutes.
Of the six who received the highest dose, all showed a reduction in the rate of bacterial growth over time, reaching peak efficacy 2 to 4 hours post-infusion.
The latter discovery was particularly pleasing to Recce, since it indicated that the drug maintains its effectiveness over a long period of time, boosting its suitability for treatment in clinical settings.
Recce’s chief medical advisor Dr. Alan Dunton said the trial results furthered the case for R327’s efficacy and safety.
“The positive outcomes from this clinical trial provide more evidence of R327 as rapid acting for the treatment of serious and life-threatening bacterial infections,” he said.
“The ability of R327 to disrupt bacterial energy production so effectively and sustain its activity over several hours highlights its potential as a transformative treatment for serious and/or resistant bacterial infections including complicated UTIs/Urosepsis.
“The mechanism is novel as an antibacterial, which has been proven safe in humans. We are excited to further explore these findings and advance R327 through subsequent trial phases.”
At 12:25 AEST, Recce was trading at 61 cents, a rise of 7.02 percent since the market opened.